Company profile
Gain Therapeutics, Inc.
NASDAQ: GANX · Healthcare · Biotechnology
#1077 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
36DFH 38DQ 33GM 36SS 41
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$20.2M
Employees
21
as of 2026-08-18
Market cap
$85.5M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$55.2k$55.2k2023
Net income-$20.2M-$20.2M2025
Operating income-$18.7M-$18.7M2025
Total assets$22.8M$22.8M2025
Liabilities$4.3M$4.3M2025
Equity$18.6M$18.6M2025
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Gain Therapeutics, Inc.’s revenue?
Gain Therapeutics, Inc. booked $55.2k in FY2023 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -36537.0% net margin.
Peers · Healthcare
Avalo Therapeutics, Inc.41DMicro Imaging Technology, Inc.——Therma Bright Inc.23DHCW Biologics Inc.31DFutureWorld Corp.——Natural Health Farm Holdings Inc.——Neighbors
Montgomery →Key facts
CEOGene Mack
SectorHealthcare
IndustryBiotechnology
HeadquartersBethesda, MD
ExchangeNASDAQ: GANX
Employees21
IPO date2021-03-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.